

PWH Antibigram 2025

GRAM NEGATIVE		ANTIBIOTICS														
1/1/2025-12/31/2025	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(b)	Levofloxacin	Meropenem	Nitrofurantoin ^(c)	Piperacillin/Tazobactam	Tetracycline	Tobramycin	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
<i>Escherichia coli</i>	522	84		84	93	88	71	#	94	72	100	96	97			80
<i>Klebsiella pneumoniae</i>	110	95		94	94	95	91	#	95	91	100	24	97			88
<i>Proteus mirabilis</i>	53	94		98	100	100	83	#	96	83	100	0	100			87
<i>Pseudomonas aeruginosa</i>	130				92		80			75	89		85			

GRAM POSITIVE		ANTIBIOTICS										
1/1/2025-12/31/2025	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin ^(c)	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE											
<i>Enterococcus faecalis</i>	118	100		9	72	99	99		82	14		93
<i>Staphylococcus aureus</i> , ALL	263		70	46		100		65		86	87	100
MRSA only	78		64	19		100		0		81	69	100
MSSA only	185		77	63		100		100		93	96	100
<i>Staphylococcus epidermidis</i> ^(a)	32		72	38		100		31		81	75	100

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant

• Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combinations not tested routinely

(a) Data with fewer than 30 isolates has poor statistical validity.

(b) Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and *Pseudomonas aeruginosa*. Gentamicin should no longer be used for the treatment of *Pseudomonas aeruginosa* infections.

(c) Nitrofurantoin should only be used for infections localized to the bladder only.